HK Stock Market Move | TYK MEDICINES-B(02410) rose more than 6% at the close of trading. TY-9591 was selected by ASCO as a breakthrough in technology for local innovative pharmaceutical companies.

TYK MEDICINES-B (02410) rose by over 6% in the final trading session, with an increase of 5.54% as of the time of reporting, reaching 57.6 Hong Kong dollars with a trading volume of 47.039 million Hong Kong dollars. In terms of news, the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting will be held in Chicago, USA from May 30 to June 3, 2025. The latest research results of TY-9591, a core product of Same source Kang Medicine, have been selected for presentation at the 2025 ASCO Annual Meeting. This will be the first appearance of TY-9591 at the ASCO Annual Meeting, and it has received an oral presentation. According to an announcement released by Same source Kang Medicine on March 9, TY-9591 (trade name: Cardasha) has shown statistically significant and clinically significant benefits in a Phase II clinical trial comparing it to osimertinib (trade name: Tagrisso) as a first-line treatment for EGFR-mutated lung cancer with brain metastasis, based on data from researchers. Due to the outstanding results of the Phase II clinical trial, TY-9591 is expected to become the world's first third-generation EGFR inhibitor approved for the indication of brain metastasis.